Urologic Diseases in America Project: Benign Prostatic Hyperplasia

Urologic Diseases in America Project: Benign Prostatic Hyperplasia

Reprinted from Vol. 173, 1256 –1261, April 2005 Printed in U.S.A. 0022-5347/05/1734-1256/0 THE JOURNAL OF UROLOGY® Copyright © 2005 by AMERICAN UROLO...

93KB Sizes 0 Downloads 7 Views

Reprinted from Vol. 173, 1256 –1261, April 2005 Printed in U.S.A.

0022-5347/05/1734-1256/0 THE JOURNAL OF UROLOGY® Copyright © 2005 by AMERICAN UROLOGICAL ASSOCIATION

DOI: 10.1097/01.ju.0000155709.37840.fe




From the Department of Urology, University of Michigan (JTW), Ann Arbor, Michigan, Department of Urology, Northwestern University (EC), Chicago, Illinois, and Division of Epidemiology, Mayo Clinic College of Medicine (SJJ), Rochester, Minnesota


Purpose: Benign prostatic hyperplasia (BPH), the most common benign neoplasm in American men, is a chronic condition that is associated with progressive lower urinary tract symptoms and affects almost 3 of 4 men during the seventh decade of life. Approximately 6.5 million of the 27 million white men who are 50 to 79 years old in the United States in 2000 were estimated to meet the criteria for discussing treatment. Materials and Methods: The analytical methods used to generate these results have been described previously. Results: In 2000 approximately 4.5 million visits were made to physician offices to for a primary diagnosis of BPH and almost 8 million visits were made with a primary or secondary diagnosis of BPH. In the same year approximately 87,400 prostatectomies for BPH were performed in inpatients in nonfederal hospitals in the United States. While the number of outpatient visits for BPH increased consistently during the 1990s, there was a dramatic decrease in the use of transurethral prostatectomy, inpatient hospitalization and length of hospital stay for this condition. These trends reflect the changing face of medical management for BPH, ie increasing use of pharmacological agents and minimally invasive therapies. In 2000 the direct cost of BPH treatment was estimated to be $1.1 billion exclusive of outpatient pharmaceuticals. Conclusions: Given the impact that BPH has on quality of life and health care cost in millions of American men, additional research into risk factors, diagnostic and therapeutic resource use, and effectiveness and cost benefit of therapies are warranted. KEY WORDS: prostate; prostatic hyperplasia; economics, medical; diagnosis; epidemiology

Benign prostatic hyperplasia (BPH) is pathologically characterized by cellular proliferation of the epithelial and stromal elements in the prostate gland. Clinically BPH is distinguished by progressive development of lower urinary tract symptoms (LUTS). These symptoms are variable and range from nocturia, incomplete emptying, urinary hesitancy, weak stream, frequency and urgency to the development of acute urinary retention. Such symptoms can have a significant negative impact on quality of life, leading many men to seek treatment.1 While no standard definition of BPH exists, clinically significant BPH is heralded by the onset of LUTS and, therefore, LUTS are usually presumed to be due to BPH in the absence of other relevant diagnoses. In this review data from the Urologic Diseases in America BPH project are presented with an emphasis on health resource use trends between 1990 and 2000. The burden of illness attributable to BPH and its associated medical care are characterized from various data sources, including administrative data sets using International Classification of Diseases-9 and Current Procedural Terminology codes, large national health surveys and community based studies with methods reported elsewhere.2, 3


Prevalence and natural history. Recent data from National Health and Nutrition Examination Survey-III suggest that BPH and LUTS are common in men 30 years or older and they increase with age, while nocturia was the most prevalent of the obstructive symptoms measured.4 Of 60 to 69year-old men almost 3 of 4 complained of nocturia and the proportion was almost 83% in men 70 years or older, illustrating the increasing burden of LUTS that occurs with aging. However, a few symptoms in and of themselves may not be sufficiently bothersome to patients to lead them to seek medical attention. Therefore, moderate to severe LUTS, defined as an American Urological Association Symptom Score of (AUASI) greater than 7 in population based studies, such as the Olmsted County Study (OCS) and Flint Men’s Health Study (FMHS), have been used to refine the estimates of prevalence, incidence and natural history of BPH.5, 6 In OCS the prevalence of moderate to severe LUTS was 26%, 33%, 41% and 46% in men in the fifth, sixth, seventh and eighth and older decades of life, respectively.5, 7 In a parallel study FMHS reported moderate to severe LUTS in 39.6% of black American men, also with a strong age association.6 Collectively all of these studies illustrate the tremendous prevalence of LUTS and document the burden of it that occurs with Submitted for publication September 8, 2004. increasing age. * Correspondence: University of Michigan Urology Center, Room The natural history of BPH/LUTS is more accurately esti1013, Women’s Trailer, 1500 East Medical Center Dr., Ann Arbor, Michigan 48109-0330 (telephone: 734-615-3040; FAX: 734-936-9536; mated in community based cohorts than in self-selected pae-mail: [email protected]). tients seeking medical attention. The former are more likely to † Financial interest and/or other relationship with Sanofi, Laser- represent the full spectrum of illness and less likely to be biased scope, Glaxo and Calypso. by socioeconomic factors, such as access to health care. OCS See Editorial on page 1065. longitudinal data suggest an annual prostate growth rate of S75 Please cite this article as J Urol 2008;179: S75–S80. DOI: 10.1016/j.juro.2008.03.141. Copyright © 2008 by AMERICAN UROLOGICAL ASSOCIATION.



1.6%, as measured by transrectal ultrasonography (TRUS),8 and an average annual increase of 0.2 AUASI point. At a median followup of 42 months in OCS the proportion of men reporting moderate to severe LUTS increased from 33% to 49%.9 Urinary retention, considered to represent a final symptomatic stage of progressive BPH, occurred in OCS at an overall incidence of 6.8 episodes per 1,000 person-years of followup and subset analyses revealed 34.7 episodes per 1,000 person-years of followup in men 70 years or older who had moderate to severe symptoms.10 These rates are comparable to data subsequently reported in the Health Professionals Followup Study, in which men 45 to 83 years old were followed from 1992 to 1997.11 In 82 men acute urinary retention developed during 15,851 person-years of followup. The 2 studies showed that age, more severe symptoms and larger prostate size were associated with an increase in the risk of urinary retention. OCS data also revealed much about risk factors for BPH. Age, prostate volume and peak urinary flow rate were each significantly associated with AUASI scores but they accounted for only 13% of symptom variability. The odds of moderate to severe symptoms increased with age after the fifth decade of life from 1.9 to 2.9 to 3.4 in men in the sixth, seventh and eighth decades, respectively. Even after adjusting for age the odds of moderate to severe symptoms were 3.5 times greater in men with a prostate larger than 50 cc on TRUS than in men with a smaller prostate. In addition, peak urinary flow less than 10 ml per second was associated with a 2.4-fold risk of moderate to severe symptoms.10 OCS data also showed that age was associated with an increased risk of acute urinary retention. After adjusting for baseline symptom severity and peak urinary flow rate the relative risk of urinary retention increased after the fifth decade of life from 0.9 to 2.1 to 4.8 in men in the sixth, seventh and eighth decades, respectively. Men with baseline AUASI greater than 7 and peak flow rates of 12 ml per second or less were 2.3 and 2.1 times more likely to have urinary retention, respectively.10 After multivariate adjustment increasing age, moderate to severe LUTS, decreased peak flow rate and prostate size (or prostate specific antigen) were associated with an increased likelihood of receiving BPH treatment. Outpatient visits. Unequivocally the first point of entry for almost all patients with BPH is the outpatient setting. In this regard we observed an increase in the number of outpatient visits for BPH from 10,116/100,000 in 1994 to 14,473/100,000 in 2000 (table 1). BPH related visits to emergency rooms decreased from 330/100,000 in 1994 to 218/100,000 in 2000 (table 2). The reasons for the increase in outpatient visits could not be examined based on available administrative

TABLE 1. National physician office and hospital outpatient visits for BPH and LUTS (National Hospital Ambulatory Medical Care Survey-Outpatient File, 1994, 1996, 1998 and 2000, and NAMCS, 1994, 1996, 1998 and 2000) Count

Rate (95% CI)

1994: Primary reason 2,899,300 6,371 (5,495–7,248) Any reason 4,603,426 10,116 (8,826–11,406) 1996: Primary reason 3,658,367 7,484 (6,294–8,675) Any reason 6,112,287 12,505 (10,856–14,153) 1998: Primary reason 3,990,359 7,754 (6,281–9,226) Any reason 6,443,185 12,520 (10,531–14,508) 2000: Primary reason 4,418,425 8,201 (6,765–9,637) Any reason 7,797,781 14,473 (12,406–16,540) Rate per 100,000 based on 1994, 1996, 1998 and 2000 population estimates from Current Population Survey, (CPS Utilities Research Corp., College Station, Texas) for relevant demographic categories of American male civilian noninstitutionalized population 40 years or older.

TABLE 2. National emergency room visits by adult males with BPH and/or LUTS listed as primary diagnosis (National Hospital Ambulatory Medical Care Survey-ER File, 1994, 1996, 1998 and 2000) Count

Rate (95% CI)

1994 150,377 330 (201–460) 1996 117,716 241 (130–352) 1998 155,923 303 (194–412) 2000 117,413 218 (117–319) Rate per 100,000 based on 1994, 1996, 1998 and 2000 Current Population Survey population estimates for relevant demographic categories of American male civilian noninstitutionalized population 40 years or older.

data. However, one can reasonably assume that these visits included clinical evaluations such as imaging, and prescriptions for medical and surgical interventions. Clinical evaluations. The excretory urogram (IVP) and TRUS have been the most commonly used imaging examinations for BPH.12 Notably since the dissemination of the BPH guidelines in 1994, the use of IVP and TRUS in the Medicare population has decreased consistently (table 3).13 By 1998 use rates for IVP and TRUS were only 986/100,000 and 3,497/100,000 cases, respectively. Computerized tomography (CT) was uncommonly used to evaluate BPH. However, other tests for assessing lower urinary tract function, including uroflowmetry and pressure flow studies, increased, while the use of cystometrograms decreased modestly based on Medicare claims data between 1991 and 1995 (table 4). These data were substantiated by the 1997 AUA Gallup Poll survey of practicing urologists in the United States who reported a decrease in the use of IVP, uroflowmetry and urodynamic studies. Moreover, high use rates for measuring post-void bladder residual urine and serum prostate specific antigen in men with BPH were seen (71% and 92%, respectively).14 In 2003 the updated AUA guidelines were disseminated and to our knowledge the impact of these guidelines has yet to be evaluated.15 Pharmacological management. In contemporary practice ␣-blockers and 5␣-reductase inhibitors are first line therapy in men with symptomatic BPH and LUTS. The AUA Gallup Poll showed that 88% of urologists recommended ␣-blockers in men with moderate urinary symptoms and evidence of prostate enlargement less than 40 cc.14 These findings are supported by data from the National Ambulatory Medical Care Survey (NAMCS) (table 5), which show that terazosin was the primary pharmacological agent, prescribed in 14% to 15% of visits for BPH between 1994 and 1996. With the subsequent introduction of more selective agents terazosin was replaced by doxazosin and tamsulosin, which together in 2000 represented 23% of the prescriptions written at BPH related outpatient visits. In contrast, the proportion of BPH outpatient visits in which finasteride was prescribed remained relatively stable (6.5% and 7.3% in 1994 and 2000, respectively) (table 5). Justification of such widespread use of these pharmacological agents can be readily found in the clinical literature.16 –19 Perhaps one of the most important studies done to date for BPH is the Medical Therapy of Prostatic Symptoms Study, a multicenter randomized, controlled trial that evaluated whether treatment with doxazosin (an ␣-blocker) or finasteride (a 5␣-reductase inhibitor) alone or in combination was more effective than placebo for preventing the clinical progression of BPH. Clinical progression was defined as worsening in the AUASI score of 4 points or more, acute urinary retention, incontinence, renal insufficiency or recurrent urinary tract infection. This randomized clinical trial demonstrated that combination therapy was almost twice as effective as monotherapy for decreasing the risk of progression (66% for the combination, 39% for doxazosin and 34% for finasteride).18



TABLE 3. Imaging for BPH and/or LUTS evaluation in male Medicare population (Centers for Medicare and Medicaid Services, 5% file, 1992, 1995 and 1998) 1992 Count

1995 Rate


1998 Rate



Totals 217,760 14,977 133,580 8,107 76,380 IVP: 56,280 3,871 25,400 1,542 14,760 Ambulatory surgery center 6,600 454 3,460 210 1,560 Inpt 8,120 558 2,760 168 2,080 Hospital outpt 920 63 520 32 260 Physician office 40,640 2,795 18,660 1,132 10,860 TRUS: 150,960 10,382 99,560 6,042 52,360 Ambulatory surgery center 5,760 396 4,940 300 4,060 Inpt 3,880 267 1,660 101 1,440 Hospital outpt 900 62 620 38 440 Physician office 140,420 9,657 92,340 5,604 46,420 Abdomen/pelvis CT with contrast medium: 5,700 392 5,200 316 5,220 Ambulatory surgery center 320 22 160 9.7 140 Inpt 2,660 183 2,460 149 3,040 Hospital outpt 80 5.5 100 6.1 60 Physician office 2,640 182 2,480 151 1,980 Abdomen/pelvis CT without contrast medium: 2,420 166 1,680 102 2,460 Ambulatory surgery center 140 9.6 60 3.6 100 Inpt 1,160 80 920 56 1,440 Hospital outpt 20 1.4 0 20 Physician office 1,100 76 700 42 900 Abdomen/pelvis CT with ⫹ without contrast medium: 1,900 131 1,520 92 1,460 Ambulatory surgery center 180 12 140 8.5 80 Inpt 560 39 660 40 620 Hospital outpt 20 1.4 60 3.6 0 Physician office 1,140 78 660 40 760 Inpt abdomen CT, contrast material use unspecified 500 35 220 13 120 Unweighted counts multiplied by 20 to arrive at values and rate per 100,000 men with BPH (counts less than 600 should be interpreted with

5,101 986 104 139 17 725 3,497 271 96 29 3,100 349 9.3 203 4.0 132 164 6.7 96 1.3 60 97 5.3 41 51 8.0 caution).

TABLE 4. Diagnostic studies for LUTS in elderly male Medicare beneficiaries (J Urol, 160: 816, 1998) Uroflowmetry: Complex Simple Cystometrogram: Complex Simple Pressure flow study: Bladder Intra-abdominal For 5% sample, 1991 to 1995.

No. 1991

No. 1992

No. 1993

No. 1994

No. 1995

6,717 1,059

7,575 936

8,528 802

8,687 608

8,607 535

2,146 622

2,081 535

1,905 463

1,978 450

1,917 414

274 183

324 226

354 238

492 329

514 343

TABLE 5. National count of prescriptions written at physician offices during visits for BPH and/or LUTS (NAMCS, 1992, 1994, 1996, 1998 and 2000) Terazosin




1994: No. prescriptions 688,717 * * 289,070 % BPH visits for which prescription was given 15 * * 6.5 1996: No. prescriptions 830,314 * * * % BPH visits for which prescription was given 14 * * * 2000: No. prescriptions * 819,043 870,889 552,483 % BPH visits for which prescription was given * 11 12 7.3 For 1992 and 1998 data on number of prescriptions and percent of visits for which prescription was given do not meet standard for reliability or precision. * Value does not meet standard for reliability or precision.

Surgical management. Historically transurethral resection of the prostate (TURP) was the second most commonly performed operation in the United States. However, with the introduction of effective alternatives to surgery urologists have increasingly used pharmacological therapy and minimally invasive procedures.14 In turn, this led to a dramatic decrease in hospitalizations for TURP throughout the 1990s, most notably between 1992 and 1995 (tables 6 and 7).20 In men older than 65 years Medicare data show that outpatient surgery for BPH decreased across almost all patient age, racial/ethnic and geographic strata (table 8). Specifically sur-

gical visits by Medicare beneficiaries decreased from 491/ 100,000 in 1992 to 372/100,000 in 2000. In those hospitalized for BPH surgery length of stay (LOS) was shorter, consistent with trends following the widespread adoption of prospective payment and managed care systems (table 9). By 2000 mean LOS was less than 3 days in all except the most elderly patients. In the 1990s a number of minimally invasive surgical therapies (MIST) were introduced, including laser ablation, transurethral needle ablation (TUNA), transurethral microwave therapy (TUMT), high energy focused ultrasound and



TABLE 6. Inpatient surgical procedures to treat BPH symptoms (HCUP Nationwide Inpatient Sample, 1994, 1996, 1998 and 2000) Surgical Procedure

No. 1994

No. 1996

No. 1998

No. 2000

Open prostatectomy TURP Balloon dilation Laser prostatectomy TUNA TUMT

5,648 136,377 279 0 0 0

4,617 103,644 161 10,616 0 0

4,341 88,907 148 3,019 0 0

4,354 87,407 161 2,045 35 14

TABLE 7. Inpatient stays by male Medicare beneficiaries with BPH and/or LUTS listed as primary diagnosis (Centers for Medicare and Medicaid Services, MedPAR and 5% Carrier Files, 1992, 1995 and 1998) 1992 Count

1995 Rate (95% CI)


Rate (95% CI)

1998 Count

Rate (95% CI)

Age: Totals 154,320 1,048 (1,043–1,053) 82,060 539 (535–543) 59,760 413 (409–416) Younger than 65 5,420 175 (171–180) 3,240 94 (91–97) 2,600 76 (73–79) 65 or Older 148,900 1,280 (1,273–1,286) 78,820 669 (665–674) 57,160 518 (513–522) 65–74 78,240 1,081 (1,073–1,089) 37,600 523 (518–528) 25,380 395 (390–400) 75–84 57,800 1,637 (1,623–1,650) 33,580 918 (908–928) 25,340 692 (684–701) 85–94 12,560 1,589 (1,562–1,617) 7,420 875 (855–894) 6,320 730 (712–748) 95 or Older 300 386 (343–430) 220 268 (233–304) 120 137 (113–161) Race/ethnicity: White 135,820 1,095 (1,089–1,101) 72,260 556 (552–560) 52,600 430 (426–434) Black 10,380 815 (799–830) 6,820 493 (481–504) 4,180 313 (304–323) Asian Not available Not available 180 247 (211–283) 560 408 (375–442) Hispanic Not available Not available 1,080 544 (512–576) 1,240 369 (349–390) North American native Not available Not available 60 298 (224–373) 120 429 (354–504) Region: Midwest 39,400 1,062 (1,052–1,073) 21,440 556 (549–564) 16,920 458 (451–464) Northeast 35,780 1,128 (1,117–1,140) 17,540 551 (543–560) 10,960 394 (387–402) South 55,840 1,066 (1,057–1,075) 28,020 511 (505–517) 21,600 402 (397–408) West 20,740 923 (911–936) 13,080 564 (554–574) 9,180 410 (402–419) Unweighted counts were multiplied by 20 to arrive at values and rate per 100,000 Medicare beneficiaries in same demographic stratum with persons of other races, unknown race and ethnicity, and other region included in totals (counts less than 600 should be interpreted with caution).

TABLE 8. Visits to ambulatory surgery centers by male Medicare beneficiaries for BPH and/or LUTS listed as primary diagnosis (Centers for Medicare and Medicaid Services, 5% Carrier and Outpatient Files, 1992, 1995 and 1998) 1992 Count

1995 Rate (95% CI)


1998 Rate (95% CI)


Rate (95% CI)

Age: Totals 72,260 491 (487–494) 62,520 411 (408–14) 53,900 372 (369–375) Younger than 65 3,340 108 (104–112) 3,720 108 (105–111) 3,480 101 (98–105) 65 or Older 68,920 592 (588–597) 58,800 499 (495–503) 50,420 457 (453–461) 65–74 41,080 568 (562–573) 33,380 464 (460–469) 26,660 415 (410–420) 75–84 23,940 678 (669–686) 21,680 593 (585–601) 19,540 534 (526–541) 85–94 3,780 478 (463–493) 3,580 422 (408–436) 4,120 476 (461–490) 95 or Older 120 155 (128–182) 160 195 (165–226) 100 114 (92–137) Race/ethnicity: White 62,580 505 (501–509) 54,820 422 (418–425) 47,220 386 (383–390) Black 5,700 447 (436–459) 5,620 406 (395–416) 4,220 316 (307–326) Asian Not available Not available 280 384 (339–429) 400 292 (263–320) Hispanic Not available Not available 480 242 (220–263) 1,020 304 (285–323) North American native Not available Not available Not available Not available Not available Not available Region: Midwest 24,840 670 (661–678) 19,480 505 (498–512) 17,420 471 (464–478) Northeast 18,640 588 (579–596) 12,900 406 (399–413) 11,480 413 (406–421) South 24,660 471 (465–477) 24,960 455 (449–461) 20,040 373 (368–379) West 4,100 182 (177–188) 5,040 217 (211–223) 4,880 218 (212–224) Unweighted counts were multiplied by 20 to arrive at values and rate per 100,000 Medicare beneficiaries in the same demographic stratum with persons of other races, unknown race and ethnicity, and other region included in totals (counts less than 600 should be interpreted with caution).

hot water thermotherapy. The 1997 AUA Gallup Poll of practicing urologists indicated that, while 95% had performed TURP in the prior year, 26% had performed laser prostatectomy, while only 3% had performed TUNA or TUMT.14 According to data from the Healthcare Cost and Utilization Project (HCUP) of MIST procedures performed in the inpatient setting only TUNA and TUMT had increased by the end of the decade (table 6), while the use of laser prostatectomy decreased. Simultaneously BPH procedures in ambulatory surgery setting had increased substantially toward the end of the decade from 264/100,000 in 1998 to 357/100,000 in 2000

based on data from commercially insured men 65 to 74 years old (data not shown). Little is known about decision making for proceeding with surgical and minimally invasive therapies. In one of the few such studies age adjusted data from National Health and Nutrition Examination Survey-III revealed no difference in the odds of BPH surgery by racial/ ethnic group, education, geographic region or urban/rural area, although never married men were 70% less likely to have undergone BPH surgery.4 Economic impact. The economic burden of BPH can be stratified into 3 areas, namely 1) direct medical costs associ-


BENIGN PROSTATIC HYPERPLASIA TABLE 9. Trends in inpatient LOS in adult males hospitalized with BPH and/or LUTS listed as primary diagnosis (HCUP Nationwide Inpatient Sample, 1994, 1996, 1998 and 2000) Mean LOS (days)

All Age: 40–44 45–54 55–64 65–74 75–84 85 or Older Race/ethnicity: White Black Asian/Pacific Islander Hispanic Other Region: Midwest Northeast South West Metropolitan statistical area: Rural Urban









3.3 3.1 3.2 3.5 4.2 5.3

2.2 2.6 2.6 2.9 3.4 4.4

2.8 2.6 2.8 2.9 3.3 4.3

3.3 2.1 2.4 2.7 3.0 4.0

3.7 4.5 2.9 3.9 4.5

3.1 3.5 2.9 3.4 2.9

3.1 3.6 3.1 3.7 3.2

2.8 3.6 3.1 2.9 3.1

3.8 4.8 3.6 2.7

3.3 3.7 3.0 2.4

3.2 3.7 2.9 2.7

2.9 3.2 2.8 2.4

3.7 3.8

3.1 3.1

3.0 3.1

2.8 2.8

ated with treatment, 2) indirect costs associated with absenteeism, work limitations and premature mortality, and 3) intangible costs associated with pain, suffering and grief. Direct Costs: We estimated that the direct cost of medical services provided at hospital inpatient and outpatient settings, emergency departments and physician offices to treat BPH in the United States in 2000 was approximately $1.1 billion. This estimate does not include the costs of outpatient prescriptions and nonprescription medications or alternative medicine visits reported by a small percent of men with BPH, nor does it include indirect and intangible costs. After adjusting for inflation total medical spending for BPH has decreased with time, particularly in the Medicare population. This decrease in spending is largely attributable to a dramatic decrease in inpatient expenditures. Total hospitalization spending for BPH decreased by more than half in Medicare beneficiaries 65 years or older from $743 million in 1992 to $315 million in 1998 (in nominal dollars). Spending on outpatient prescription drugs for BPH treatment in 1996 to 1998 was $194 million annually according to estimates from the Medical Expenditure Panel Survey. The majority of prescriptions and pharmacy spending were for terazosin, followed by doxazosin and finasteride (table 10). To examine the incremental medical costs associated with a diagnosis of BPH we used data on 280,000 primary beneficiaries 18 to 64 years old with employer provided insurance coverage in 1999. We estimated medical expenditures in per-

TABLE 10. Annual spending and select outpatient prescription drugs for BPH in 1996 to 1998 (Medical Expenditure Panel Survey, 1996 to 1998) Drug Name

No. Prescription Claims

Mean Price ($)

Mean Total Expenditures ($)

Terazosin Doxazosin Finasteride

1,923,054 605,744 518,038

67.39 49.26 66.77

129,594,632 29,838,949 34,589,375

Total 194,022,956 Estimates include prescription drug claims with corresponding diagnosis of BPH and exclude drugs for which number of claims could not be reliably estimated due to data limitations since including expenditures for excluded prescription drugs for which number of claims could not be reliably estimated would increase total drug spending by approximately 2% to $198.6 million.

sons with and without a primary diagnosis of BPH in 1999, controlling for differences in insurance coverage (medical and drug benefits), patient demographics and health status (medical comorbidities). Based on these data we estimated that the incremental direct annual medical costs for BPH were $2,577. The average annual cost in men without a BPH claim was $3,138, while the claim in those with BPH was $5,715. Indirect Costs: Work lost by men with BPH was measured in 1999 (MarketScan, Chichester, United Kingdom). A tenth of the men with BPH missed work, losing an average of 7.3 hours annually. Each visit for outpatient care was associated with an average work loss of 4.7 hours. With an estimated 4.5 million visits with a primary diagnosis of BPH and almost 8 million visits with BPH as a primary or secondary diagnosis of BPH there is a significant loss to society of between 21 million and 38 million hours of lost productivity. Therefore, the inclusion of indirect costs would certainly increase the estimates of the overall economic burden of BPH. DISCUSSION

The tremendous prevalence of BPH and its associated high cost of care affirms not only the conviction that this is an important chronic condition, but also that government and other health care payers must constantly examine patterns of care to optimize quality and cost. The prevalence and natural history of BPH have been well studied in the last decade of the millennium and our appreciation of the clinical manifestations from mild symptoms to urinary retention is fairly clear. However, the perspective taken in these studies has almost universally considered the clinical perspective to the exclusion of the broader public health picture. For example, one can readily quote OCS data that show an increasing likelihood of moderate to severe symptoms with increasing age decades but one cannot easily express what is the most cost-effective long-term care in a patient presenting with moderate to severe symptoms due to BPH. As a result, almost all patients presenting with LUTS are prescribed medical management as initial therapy almost by default. Does this represent good quality of care? As a consequence of physicians prescribing increasingly more oral therapies for BPH, there has been an extraordinary shift in BPH management from surgical to medical care. The net effect of this phenomenon is that BPH has transformed from a pseudo-acute condition (that is a symptomatic condition that was promptly treated with surgery) to a bona fide chronic condition requiring ongoing medication and medical care. The public health impact of this paradigm shift on the American population is wholly unclear but unlikely to be trivial. For example, note clinical studies that establish a risk decrease of 5␣-reductase inhibitors on urinary retention and TURP. Do we know if men who undergo initial surgery are more or less satisfied than those who are treated medically? Does this change after 5 or 10 years of taking medication for symptoms? In fact, there are ample data to suggest that symptomatic improvement in surgical patients is much greater than in those on medical management. The picture painted by these Urologic Diseases in America data on BPH is that of a burgeoning population of aging men on medical management who increasingly need to see not only primary care physicians, but also a urologist for symptomatic BPH. If most of these men ultimately undergo minimally invasive therapy or surgical treatment, what have we achieved beyond increasing costs to society and prolonging the duration of the patient symptomatic phase? Although critics were correct in pointing out that TURP was the most common operation in the Medicare population after surgery for cataracts, it is not clear that this practice was wrong or represented overuse. Perhaps it is time for us to consider the possibility that some patients are better off in the long run with initial surgical treatment rather than with



medical treatment. Large prospective studies that capture the process of care as it relates to long-term patient outcomes using validated measures are direly needed to identify such patients and answer fundamental questions regarding quality of care. This is particularly relevant when one considers that most elderly patients expend a significant proportion of their limited monthly income on prescriptions and there is a looming prescription drug crisis in our country. Limitations. Although to our knowledge this study represents the largest comprehensive description of BPH resource use to date, there are important limitations to consider. 1) These administrative data provide a reliable overview of care but lack the detailed patient level information, such as symptom severity, duration and prior therapies, necessary to adjust for confounding. 2) Only data through 2000 were available and newer therapies (eg alfuzosin, saline TURP, photovaporization, etc) were not included. The improved safety and effectiveness of therapies such as saline TURP and photovaporization over other techniques may further decrease the threshold for patients to proceed to surgical intervention. 3) This report was based on several large administrative datasets and community based cohorts (OCS and FMHS). However, due to the lack of a standard definition for BPH, statistical cross-referencing across data sets was not possible. Future standardization would greatly facilitate research of the prevention, diagnosis and treatment of BPH. CONCLUSIONS

The substantial prevalence of BPH and its therapies attests to the tremendous impact of this condition on the health and quality of life of American men. Increasingly BPH therapy trends are moving away from the gold standard operation of TURP and toward less invasive pharmacological options and MIST in an outpatient setting. Of them the use of pharmacological approaches for BPH has had the most obvious impact. Consequently longitudinal evaluations of practice patterns in the United States should be done as newer therapies, including herbal supplements,21 gain in popularity. Such studies will also allow a better understanding of how patients progress through the spectrum of care from watchful waiting to pharmacological management to MIST and ultimately to surgical intervention. Moreover, factors important to treatment decision making, the use of updated evidence based guidelines and how they differ between primary care and urological specialists should be examined.15 Future efforts should continue to address the underlying etiology of BPH. Clinical epidemiological studies that focus on the effects of sociodemographic factors, such as race/ethnicity and access to health care, on BPH prevalence and the relationship between LUTS and other conditions, such as diabetes and sexual dysfunction, have the potential to improve care. Given the dramatic trends of the last 10 years and persistent variation in the management of BPH, quality of care delivered for BPH should be evaluated. The delivery of high quality care should be the goal of all clinicians who provide care for patients with BPH. REFERENCES

1. Jacobsen, S. J., Guess, H. A., Panser, L., Girman, C. J., Chute, C. G., Oesterling, J. E. et al: A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among Men. Arch Fam Med, 2: 729, 1993 2. Litwin, M. S., Saigal, C. S., Yano, E. M., Avila, C., Geschwind, S. A., Hanley, J. M. et al: Urologic Diseases in America Project: analytic methods and principal findings. J Urol, 173: 933, 2005 3. Litwin, M. S. and Saigal, C. S.: Urologic Diseases in America Interim Compendium. Washington, D. C.: United States Department of Health and Human Services, Public Health Service, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004

4. Platz, E. A., Smit, E., Curhan, G. C., Nyberg, L. M. and Giovannucci, E.: Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U. S. men. Urology, 59: 877, 2002 5. Chute, C. G., Panser, L. A., Girman, C. J., Oesterling, J. E., Guess, H. A., Jacobsen, S. J. et al: The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol, 150: 85, 1993 6. Wei, J. T., Schottenfeld, D., Cooper, K., Taylor, J. M., Faerber, G. J., Velarde, M. A. et al: The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness. J Urol, 165: 1521, 2001 7. Girman, C. J., Jacobsen, S. J., Guess, H. A., Oesterling, J. E., Chute, C. G., Panser, L. A. et al: Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol, 153: 1510, 1995 8. Rhodes, T., Girman, C. J., Jacobsen, S. J., Roberts, R. O., Guess, H. A. and Lieber, M. M.: Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol, 161: 1174, 1999 9. Jacobsen, S. J., Jacobson, D. J., Girman, C. J., Roberts, R. O., Rhodes, T., Guess, H. A. et al: Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol, 162: 1301, 1999 10. Jacobsen, S. J., Jacobson, D. J., Girman, C. J., Roberts, R. O., Rhodes, T., Guess, H. A. et al: Natural history of prostatism: risk factors for acute urinary retention. J Urol, 158: 481, 1997 11. Meigs, J. B., Barry, M. J., Giovannucci, E., Rimm, E. B., Stampfer, M. J. and Kawachi, I.: Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol, 162: 376, 1999 12. Andersen, J. T., Jacobsen, O. and Standgaard, L.: The diagnostic value of intravenous pyelography in infravesical obstruction in males. Scand J Urol Nephrol, 11: 225, 1977 13. McConnell, J. D., Barry, M. J. and Bruskewitz, R. C.: Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin, 8: 1, 1994 14. Gee, W. F., Holtgrewe, H. L., Blute, M. L., Miles, B. J., Naslund, M. J., Nellans, R. E. et al: 1997 American Urological Association Gallup survey: changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997. J Urol, 160: 1804, 1998 15. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol, 170: 530, 2003 16. Roehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., Andriole, G., ARIA 3001 et al: Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology, 60: 434, 2002 17. Roehrborn, C. G., Van Kerrebroeck, P. and Nordling, J.: Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebocontrolled studies. BJU Int, 92: 257, 2003 18. McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Jr., Dixon, C. M., Kusek, J. W. et al: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med, 349: 2387, 2003 19. McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L. et al: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med, 338: 557, 1998 20. Xia, Z., Roberts, R. O., Schottenfeld, D., Lieber, M. M. and Jacobsen, S. J.: Trends in prostatectomy for benign prostatic hyperplasia among black and white men in the United States: 1980 to 1994. Urology, 53: 1154, 1999 21. Boyle, P., Robertson, C., Lowe, F. and Roehrborn, C.: Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int, 93: 751, 2004